{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:31:54Z","timestamp":1794958314803,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["RIA2017S"],"award-info":[{"award-number":["RIA2017S"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["96859"],"award-info":[{"award-number":["96859"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["98341"],"award-info":[{"award-number":["98341"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00734-8","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T04:41:58Z","timestamp":1743914518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV \u2013 a review"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1449-160X","authenticated-orcid":false,"given":"Sharana","family":"Mahomed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razia","family":"Hassan-Moosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna P. G. V.","family":"Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Rose-Abrahams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,6]]},"reference":[{"key":"734_CR1","unstructured":"UNAIDS, Global HIV. & AIDS statistics \u2014 Fact sheet 2024. [Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed: December 15, 2024."},{"issue":"1","key":"734_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/17843286.2020.1770413","volume":"77","author":"J De Clercq","year":"2022","unstructured":"De Clercq J, Rutsaert S, De Scheerder M-A, Verhofstede C, Callens S, Vandekerckhove L. Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clin Belg. 2022;77(1):168\u201376.","journal-title":"Acta Clin Belg"},{"issue":"3","key":"734_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11904-022-00604-2","volume":"19","author":"EF Kreider","year":"2022","unstructured":"Kreider EF, Bar KJ. HIV-1 reservoir persistence and decay: implications for cure strategies. Curr HIV\/AIDS Rep. 2022;19(3):194\u2013206.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"5","key":"734_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/cid\/ciab541","volume":"74","author":"JZ Li","year":"2022","unstructured":"Li JZ, Aga E, Bosch RJ, Pilkinton M, Kroon E, MacLaren L, et al. Time to viral rebound after interruption of modern antiretroviral therapies. Clin Infect Dis. 2022;74(5):865\u201370.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"734_CR5","doi-asserted-by":"publisher","first-page":"e1003174","DOI":"10.1371\/journal.ppat.1003174","volume":"9","author":"S Eriksson","year":"2013","unstructured":"Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013;9(2):e1003174.","journal-title":"PLoS Pathog"},{"issue":"5","key":"734_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14787210.2020.1736561","volume":"18","author":"D Rial-Crestelo","year":"2020","unstructured":"Rial-Crestelo D, Pinto-Mart\u00ednez A, Pulido F. Cabotegravir and rilpivirine for the treatment of HIV. Expert Rev Anti Infect Ther. 2020;18(5):393\u2013404.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"734_CR7","doi-asserted-by":"crossref","unstructured":"Ndashimye E, Reyes PS, Arts EJ. New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates? FEMS Microbiol Rev. 2023;47(1).","DOI":"10.1093\/femsre\/fuac040"},{"issue":"18","key":"734_CR8","doi-asserted-by":"publisher","first-page":"11927","DOI":"10.1021\/acs.jmedchem.2c00879","volume":"65","author":"A Regueiro-Ren","year":"2022","unstructured":"Regueiro-Ren A, Sit SY, Chen Y, Chen J, Swidorski JJ, Liu Z, et al. The discovery of GSK3640254, a Next-Generation inhibitor of HIV-1 maturation. J Med Chem. 2022;65(18):11927\u201348.","journal-title":"J Med Chem"},{"key":"734_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-med-041217-013717","volume":"70","author":"RM Gulick","year":"2019","unstructured":"Gulick RM, Flexner C. Long-Acting HIV drugs for treatment and prevention. Annu Rev Med. 2019;70:137\u201350.","journal-title":"Annu Rev Med"},{"key":"734_CR10","unstructured":"World Health Organization (WHO). 2024. A seventh case of HIV cure reported at AIDS 2024."},{"issue":"27","key":"734_CR11","doi-asserted-by":"publisher","first-page":"e38768","DOI":"10.1097\/MD.0000000000038768","volume":"103","author":"EU Alum","year":"2024","unstructured":"Alum EU, Uti DE, Ugwu OP, Alum BN. Toward a cure - Advancing HIV\/AIDs treatment modalities beyond antiretroviral therapy: A review. Med (Baltim). 2024;103(27):e38768.","journal-title":"Med (Baltim)"},{"issue":"1","key":"734_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11904-016-0299-7","volume":"13","author":"KE Stephenson","year":"2016","unstructured":"Stephenson KE, Barouch DH. Broadly neutralizing antibodies for HIV eradication. Curr HIV\/AIDS Rep. 2016;13(1):31\u20137.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"734_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/infdis\/165.2.364","volume":"165","author":"D Vittecoq","year":"1992","unstructured":"Vittecoq D, Mattlinger B, Barre-Sinoussi F, Courouce AM, Rouzioux C, Doinel C, et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis. 1992;165(2):364\u20138.","journal-title":"J Infect Dis"},{"issue":"2","key":"734_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/infdis\/168.2.298","volume":"168","author":"JM Jacobson","year":"1993","unstructured":"Jacobson JM, Colman N, Ostrow NA, Simson RW, Tomesch D, Marlin L, et al. Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis. 1993;168(2):298\u2013305.","journal-title":"J Infect Dis"},{"issue":"7","key":"734_CR15","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1182\/blood.V84.7.2130.2130","volume":"84","author":"J Levy","year":"1994","unstructured":"Levy J, Youvan T, Lee ML. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The passive hyperimmune therapy study group. Blood. 1994;84(7):2130\u20135.","journal-title":"Blood"},{"issue":"4","key":"734_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1073\/pnas.92.4.1195","volume":"92","author":"D Vittecoq","year":"1995","unstructured":"Vittecoq D, Chevret S, Morand-Joubert L, Heshmati F, Audat F, Bary M, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci U S A. 1995;92(4):1195\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"734_CR17","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1073\/pnas.87.19.7613","volume":"87","author":"A Karpas","year":"1990","unstructured":"Karpas A, Hewlett IK, Hill F, Gray J, Byron N, Gilgen D, et al. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A. 1990;87(19):7613\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8612","key":"734_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0140-6736(88)90468-0","volume":"2","author":"GG Jackson","year":"1988","unstructured":"Jackson GG, Perkins JT, Rubenis M, Paul DA, Knigge M, Despotes JC, Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988;2(8612):647\u201352.","journal-title":"Lancet"},{"issue":"3","key":"734_CR19","first-page":"149","volume":"73","author":"L Morand-Joubert","year":"1997","unstructured":"Morand-Joubert L, Vittecoq D, Roudot-Thoraval F, Mariotti M, Lefr\u00e8re F, Heshmati F, et al. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies). Vox Sang. 1997;73(3):149\u201354.","journal-title":"Vox Sang"},{"issue":"5","key":"734_CR20","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/jac\/dkh428","volume":"54","author":"C Armbruster","year":"2004","unstructured":"Armbruster C, Stiegler GM, Vcelar BA, J\u00e4ger W, K\u00f6ller U, Jilch R, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12. J Antimicrob Chemother. 2004;54(5):915\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"734_CR21","doi-asserted-by":"publisher","first-page":"e116153","DOI":"10.1371\/journal.pone.0116153","volume":"9","author":"GC Morris","year":"2014","unstructured":"Morris GC, Wiggins RC, Woodhall SC, Bland JM, Taylor CR, Jespers V, et al. MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide. PLoS ONE. 2014;9(12):e116153.","journal-title":"PLoS ONE"},{"issue":"6","key":"734_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nm1244","volume":"11","author":"A Trkola","year":"2005","unstructured":"Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11(6):615\u201322.","journal-title":"Nat Med"},{"issue":"20","key":"734_CR23","doi-asserted-by":"publisher","first-page":"11016","DOI":"10.1128\/JVI.01340-07","volume":"81","author":"S Mehandru","year":"2007","unstructured":"Mehandru S, Vcelar B, Wrin T, Stiegler G, Joos B, Mohri H, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol. 2007;81(20):11016\u201331.","journal-title":"J Virol"},{"issue":"3","key":"734_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","volume":"223","author":"S Mahomed","year":"2021","unstructured":"Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review. J Infect Dis. 2021;223(3):370\u201380.","journal-title":"J Infect Dis"},{"key":"734_CR25","doi-asserted-by":"crossref","unstructured":"Thavarajah JJ, H\u00f8nge BL, Wejse CM. The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention. Viruses. 2024;16(6).","DOI":"10.3390\/v16060911"},{"issue":"8","key":"734_CR26","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1021\/acsomega.2c07933","volume":"8","author":"S Kumar","year":"2023","unstructured":"Kumar S, Singh S, Luthra K. An overview of human Anti-HIV-1 neutralizing antibodies against diverse epitopes of HIV-1. ACS Omega. 2023;8(8):7252\u201361.","journal-title":"ACS Omega"},{"issue":"1","key":"734_CR27","doi-asserted-by":"publisher","first-page":"a007039","DOI":"10.1101\/cshperspect.a007039","volume":"2","author":"J Overbaugh","year":"2012","unstructured":"Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harbor Perspect Med. 2012;2(1):a007039.","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"734_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","volume":"34","author":"DR Burton","year":"2016","unstructured":"Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016;34:635\u201359.","journal-title":"Annu Rev Immunol"},{"key":"734_CR29","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3389\/fimmu.2017.01590","volume":"8","author":"LM Mayr","year":"2017","unstructured":"Mayr LM, Su B, Moog C. Non-Neutralizing antibodies directed against HIV and their functions. Front Immunol. 2017;8:1590.","journal-title":"Front Immunol"},{"issue":"4","key":"734_CR30","doi-asserted-by":"publisher","first-page":"e1006987","DOI":"10.1371\/journal.ppat.1006987","volume":"14","author":"SI Richardson","year":"2018","unstructured":"Richardson SI, Chung AW, Natarajan H, Mabvakure B, Mkhize NN, Garrett N, et al. HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathog. 2018;14(4):e1006987.","journal-title":"PLoS Pathog"},{"issue":"1","key":"734_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12977-018-0455-9","volume":"15","author":"H Gruell","year":"2018","unstructured":"Gruell H, Klein F. Antibody-mediated prevention and treatment of HIV-1 infection. Retrovirology. 2018;15(1):73.","journal-title":"Retrovirology"},{"issue":"7427","key":"734_CR32","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature11604","volume":"492","author":"F Klein","year":"2012","unstructured":"Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118\u201322.","journal-title":"Nature"},{"issue":"7475","key":"734_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature12746","volume":"503","author":"M Shingai","year":"2013","unstructured":"Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277\u201380.","journal-title":"Nature"},{"key":"734_CR34","doi-asserted-by":"publisher","first-page":"690017","DOI":"10.3389\/fpubh.2021.690017","volume":"9","author":"DA Spencer","year":"2021","unstructured":"Spencer DA, Shapiro MB, Haigwood NL, Hessell AJ. Advancing HIV broadly neutralizing antibodies: from discovery to the clinic. Front Public Health. 2021;9:690017.","journal-title":"Front Public Health"},{"key":"734_CR35","doi-asserted-by":"publisher","first-page":"708227","DOI":"10.3389\/fimmu.2021.708227","volume":"12","author":"SA Griffith","year":"2021","unstructured":"Griffith SA, McCoy LE. To BnAb or not to BnAb: defining broadly neutralising antibodies against HIV-1. Front Immunol. 2021;12:708227.","journal-title":"Front Immunol"},{"issue":"2","key":"734_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl J, Baxter AE, Mendoza P, Jankovic M, Cohen YZ, Butler AL, et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat Med. 2020;26(2):222\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"734_CR37","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1038\/s41467-022-34171-2","volume":"13","author":"M Ros\u00e1s-Umbert","year":"2022","unstructured":"Ros\u00e1s-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity. Nat Commun. 2022;13(1):6473.","journal-title":"Nat Commun"},{"issue":"6288","key":"734_CR38","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs T, Klein F, Braunschweig M, Kreider EF, Feldmann A, Nogueira L, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352(6288):997\u20131001.","journal-title":"Science"},{"key":"734_CR39","doi-asserted-by":"publisher","first-page":"105788","DOI":"10.1016\/j.antiviral.2023.105788","volume":"222","author":"AI Schriek","year":"2024","unstructured":"Schriek AI, Aldon YLT, van Gils MJ, de Taeye SW. Next-generation bNAbs for HIV-1 cure strategies. Antiviral Res. 2024;222:105788.","journal-title":"Antiviral Res"},{"issue":"4","key":"734_CR40","doi-asserted-by":"publisher","first-page":"e1010467","DOI":"10.1371\/journal.ppat.1010467","volume":"18","author":"B Moldt","year":"2022","unstructured":"Moldt B, Chandrashekar A, Borducchi EN, Nkolola JP, Stephenson H, Nagel M, et al. HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. PLoS Pathog. 2022;18(4):e1010467.","journal-title":"PLoS Pathog"},{"issue":"15","key":"734_CR41","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1097\/00002030-200210180-00006","volume":"16","author":"G Stiegler","year":"2002","unstructured":"Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. Aids. 2002;16(15):2019\u201325.","journal-title":"Aids"},{"issue":"5730","key":"734_CR42","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1126\/science.1111781","volume":"308","author":"BF Haynes","year":"2005","unstructured":"Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308(5730):1906\u20138.","journal-title":"Science"},{"issue":"2","key":"734_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1084\/jem.20121977","volume":"210","author":"G Yang","year":"2013","unstructured":"Yang G, Holl TM, Liu Y, Li Y, Lu X, Nicely NI, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210(2):241\u201356.","journal-title":"J Exp Med"},{"issue":"11","key":"734_CR44","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"L Corey","year":"2021","unstructured":"Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodi NM, Decamp AC, Rudnicki E, Huang Y. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021;384(11):1003\u201314.","journal-title":"N Engl J Med"},{"key":"734_CR45","doi-asserted-by":"crossref","unstructured":"Houser KV, Gaudinski MR, Happe M, Narpala S, Verardi R, Sarfo EK, Corrigan AR, Wu R, Rothwell RS, Novik L, Hendel CS. Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. EClinicalMedicine. 2022;48.","DOI":"10.1016\/j.eclinm.2022.101477"},{"key":"734_CR46","doi-asserted-by":"publisher","first-page":"e46767","DOI":"10.2196\/46767","volume":"9","author":"W Wang","year":"2023","unstructured":"Wang W, Zhao S, Wu Y, Duan W, Li S, Li Z, Guo C, Wang W, Zhang T, Wu H, Huang X. Safety and efficacy of long-acting injectable agents for HIV-1: systematic review and meta-analysis. JMIR Public Health Surveill. 2023;9:e46767.","journal-title":"JMIR Public Health Surveill"},{"issue":"7","key":"734_CR47","doi-asserted-by":"publisher","first-page":"e175375","DOI":"10.1172\/jci.insight.175375","volume":"9","author":"SF Awan","year":"2024","unstructured":"Awan SF, Pegu A, Strom L, Carter CA, Hendel CS, Holman LA, Costner PJ, Trofymenko O, Dyer R, Gordon IJ, Rothwell RS. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS. JCI Insight. 2024;9(7):e175375.","journal-title":"JCI Insight"},{"issue":"8","key":"734_CR48","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","volume":"14","author":"YZ Cohen","year":"2019","unstructured":"Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O\u2019Brien C, et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS ONE. 2019;14(8):e0219142.","journal-title":"PLoS ONE"},{"issue":"5","key":"734_CR49","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","volume":"28","author":"JP Casazza","year":"2022","unstructured":"Casazza JP, Cale EM, Narpala S, Yamshchikov GV, Coates EE, Hendel CS, et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med. 2022;28(5):1022\u201330.","journal-title":"Nat Med"},{"issue":"319","key":"734_CR50","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206.","journal-title":"Sci Transl Med"},{"issue":"10","key":"734_CR51","doi-asserted-by":"publisher","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","volume":"5","author":"SA Riddler","year":"2018","unstructured":"Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect Dis. 2018;5(10):ofy242.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"734_CR52","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","volume":"6","author":"TA Crowell","year":"2019","unstructured":"Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV. 2019;6(5):e297\u2013306.","journal-title":"Lancet HIV"},{"issue":"6","key":"734_CR53","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1172\/JCI134395","volume":"130","author":"EM Cale","year":"2020","unstructured":"Cale EM, Bai H, Bose M, Messina MA, Colby DJ, Sanders-Buell E, et al. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. J Clin Invest. 2020;130(6):3299\u2013304.","journal-title":"J Clin Invest"},{"issue":"21","key":"734_CR54","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med. 2016;375(21):2037\u201350.","journal-title":"N Engl J Med"},{"issue":"7","key":"734_CR55","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1172\/JCI120194","volume":"128","author":"DB Salantes","year":"2018","unstructured":"Salantes DB, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, et al. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest. 2018;128(7):3102\u201315.","journal-title":"J Clin Invest"},{"issue":"1","key":"734_CR56","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41467-022-28727-5","volume":"13","author":"DR Beckford-Vera","year":"2022","unstructured":"Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, et al. First-in-human ImmunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. 2022;13(1):1219.","journal-title":"Nat Commun"},{"key":"734_CR57","unstructured":"Karuna S, Bar K, deCamp A et al. Analytical treatment interruption among African women and Peruvian men & transgender individuals with early ART initiation +\/- VRC01 circulating at HIV acquisition: Early observations of viral rebound & control. Oral presentation at the 12th International AIDS Society (IAS) conference on HIV Science. 2023 July: 23-26."},{"issue":"5","key":"734_CR58","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jiab487","volume":"225","author":"CL Gay","year":"2022","unstructured":"Gay CL, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Moeser MJ, et al. Stable latent HIV infection and Low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat. J Infect Dis. 2022;225(5):856\u201361.","journal-title":"J Infect Dis"},{"issue":"7557","key":"734_CR59","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr., Buckley N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487\u201391.","journal-title":"Nature"},{"issue":"7613","key":"734_CR60","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556\u201360.","journal-title":"Nature"},{"issue":"9","key":"734_CR61","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1084\/jem.20180936","volume":"215","author":"YZ Cohen","year":"2018","unstructured":"Cohen YZ, Lorenzi JCC, Krassnig L, Barton JP, Burke L, Pai J, et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med. 2018;215(9):2311\u201324.","journal-title":"J Exp Med"},{"key":"734_CR62","doi-asserted-by":"publisher","first-page":"103252","DOI":"10.1016\/j.ebiom.2021.103252","volume":"65","author":"JH McMahon","year":"2021","unstructured":"McMahon JH, Zerbato JM, Lau JSY, Lange JL, Roche M, Tumpach C, et al. A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. EBioMedicine. 2021;65:103252.","journal-title":"EBioMedicine"},{"issue":"2","key":"734_CR63","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185\u201391.","journal-title":"Nat Med"},{"issue":"10","key":"734_CR64","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021;27(10):1718\u201324.","journal-title":"Nat Med"},{"issue":"7724","key":"734_CR65","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479\u201384.","journal-title":"Nature"},{"issue":"11","key":"734_CR66","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018;24(11):1701\u20137.","journal-title":"Nat Med"},{"issue":"7913","key":"734_CR67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature. 2022;606(7913):375\u201381.","journal-title":"Nature"},{"issue":"7913","key":"734_CR68","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022;606(7913):368\u201374.","journal-title":"Nature"},{"issue":"6","key":"734_CR69","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022;28(6):1288\u201396.","journal-title":"Nat Med"},{"key":"734_CR70","doi-asserted-by":"crossref","unstructured":"Julg B, Walker-Sperling VE, Wagh K, Aid M, Stephenson KE, Zash R, Liu J, Nkolola JP, Hoyt A, Castro M, Serebryannyy L. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat Med. 2024;30(12):3534\u201343.","DOI":"10.1038\/s41591-024-03247-5"},{"issue":"3","key":"734_CR71","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","volume":"3","author":"H Gruell","year":"2022","unstructured":"Gruell H, Gunst JD, Cohen YZ, Pahus MH, Malin JJ, Platten M, et al. Effect of 3BNC117 and Romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe. 2022;3(3):e203\u201314.","journal-title":"Lancet Microbe"},{"issue":"11","key":"734_CR72","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst JD, Pahus MH, Ros\u00e1s-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early intervention with 3BNC117 and Romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat Med. 2022;28(11):2424\u201335.","journal-title":"Nat Med"},{"issue":"3","key":"734_CR73","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","volume":"11","author":"JJ Eron","year":"2024","unstructured":"Eron JJ, Little SJ, Crofoot G, Cook P, Ruane PJ, Jayaweera D, et al. Safety of teropavimab and Zinlirvimab with Lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024;11(3):e146\u201355.","journal-title":"Lancet HIV"},{"key":"734_CR74","unstructured":"Tebas PAL, Papasavvas E, Choi G, Ellenberg S, Caskey M, Howell B, Hazuda D, Petropoulus C, Lynn K, Chareczko L, Kostman J, Short W, Mounzer K, Montaner L. BEAT2: Peg-IFN-\u03b12b\u2009+\u20093BNC117 and 10-1074 keeps HIV at <\u200920 c\/\u00b5l during a 26-week ATI. Abstract Presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI). 2022 February:12 -16."},{"issue":"10","key":"734_CR75","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","volume":"29","author":"JD Gunst","year":"2023","unstructured":"Gunst JD, H\u00f8jen JF, Pahus MH, Ros\u00e1s-Umbert M, Stiksrud B, McMahon JH, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat Med. 2023;29(10):2547\u201358.","journal-title":"Nat Med"},{"key":"734_CR76","doi-asserted-by":"crossref","unstructured":"Yeo JY, Goh GR, Su CT, Gan SK. The determination of HIV-1 RT mutation rate, its possible allosteric effects, and its implications on drug resistance. Viruses. 2020;12(3).","DOI":"10.3390\/v12030297"},{"issue":"1","key":"734_CR77","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","volume":"9","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cao W, Sun M, Li T. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infect. 2020;9(1):194\u2013206.","journal-title":"Emerg Microbes Infect"},{"key":"734_CR78","unstructured":"Reeves J, Zheng Y, Olefsky M, Lie Y, Burke L, Taiwo B, Petropoulos C, Tebas P, Caskey M, Bar K. Susceptibility to anti-HIV bnAbs is concordant in pre-ART plasma and on-ART PBMC samples: ACTG NWCS413. Conferences on Retroviruses and Opportuninstic Infections (CROI) poster presentation, abstract number 305, March 4\u20137, 2019, Seattle, Washington."},{"issue":"1","key":"734_CR79","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13063-022-06151-w","volume":"23","author":"MJ Lee","year":"2022","unstructured":"Lee MJ, Collins S, Babalis D, Johnson N, Falaschetti E, Prevost AT, et al. The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial. Trials. 2022;23(1):263.","journal-title":"Trials"},{"issue":"1","key":"734_CR80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrmicro.2015.5","volume":"14","author":"MJ Churchill","year":"2016","unstructured":"Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R. HIV reservoirs: what, where and how to target them. Nat Rev Microbiol. 2016;14(1):55\u201360.","journal-title":"Nat Rev Microbiol"},{"key":"734_CR81","doi-asserted-by":"crossref","unstructured":"Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W et al. Twice-Yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179\u20131192.","DOI":"10.1056\/NEJMoa2407001"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00734-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00734-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00734-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T19:26:00Z","timestamp":1743967560000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00734-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00734-8","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,6]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}